Addex Therapeutics (ADXN)
NASDAQ:ADXN
Want to see ADXN full AI Analyst Report?
Top Page
Addex Therapeutics
(NASDAQ:ADXN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$5.50
▼(-33.17% Downside)
Action:Reiterated
Date:05/31/26
The score is held down primarily by weak financial performance (large ongoing losses and persistent cash burn), with only the low-debt balance sheet providing support. Technical indicators are neutral-to-slightly bearish, and valuation is unattractive/unclear due to negative earnings and no dividend.
Positive Factors
Allosteric platform focus
Addex’s proprietary allosteric modulation platform and focus on metabotropic glutamate receptors create a durable R&D advantage: platform approaches can yield multiple drug candidates, support partnering/licensing strategies, and spread discovery risk across programs over the medium term.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means Addex remains reliant on external financing or partner funding to advance programs. Even with improvement in 2025, continued cash consumption raises dilution and execution risk, constraining the company’s ability to self-fund trials or scale operations long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Allosteric platform focus
Addex’s proprietary allosteric modulation platform and focus on metabotropic glutamate receptors create a durable R&D advantage: platform approaches can yield multiple drug candidates, support partnering/licensing strategies, and spread discovery risk across programs over the medium term.
Read all positive factors
Addex Therapeutics (ADXN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.72M
Dividend YieldN/A
Average Volume (3M)16.10K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth-55.97%
EPS Growth-198.81%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.57
Shares Outstanding1,822,121
10 Day Avg. Volume4,441
30 Day Avg. Volume16,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue76.11
Enterprise Value/Gross Profit-30.04
Enterprise Value/Ebitda-0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Addex Therapeutics Business Overview & Revenue Model
Company Description
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their c...
How the Company Makes Money
Addex Therapeutics primarily aims to generate revenue through partnering its drug candidates and technology with larger pharmaceutical or biotechnology companies. Under this model, the company can receive (1) upfront payments when entering collabo...
Addex Therapeutics Earnings Call Summary
Earnings Call Date:Dec 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 24, 2026
Earnings Call Sentiment Neutral
The call highlighted significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.Positive Updates
Progress in GABAB PAM and Dipraglurant Programs
Addex Therapeutics made excellent progress in their GABAB PAM program for chronic cough and dipraglurant post-stroke recovery. Preclinical characterization and IND-enabling studies have been successfully completed.
Negative Updates
Limited Funding for Unpartnered Programs
Current cash does not fund progression of unpartnered programs into the clinic, indicating a potential gap in financing for further development.
Read all updates
Q3-2025 Updates
Positive
Negative
Progress in GABAB PAM and Dipraglurant Programs
Addex Therapeutics made excellent progress in their GABAB PAM program for chronic cough and dipraglurant post-stroke recovery. Preclinical characterization and IND-enabling studies have been successfully completed.
Read all positive updates
Company Guidance
During the Addex Therapeutics Third Quarter 2025 Financial Results and Corporate Update Conference Call, significant guidance was provided. Addex reported progress in their GABAB PAM program, selecting a backup compound and emphasizing their eligibility for up to USD 330 million in milestone payments from their partner, Indivior. They highlighted advancements in their dipraglurant post-stroke recovery program, aiming to address a growing need among over 100 million stroke survivors. Financially, Addex ended Q3 2025 with CHF 2.2 million in cash, ensuring liquidity through mid-2026, although it doesn't cover unpartnered programs. Their investment in Neurosterix, which is progressing with its M4 PAM schizophrenia program, and Stalicla, which is focusing on neurodevelopmental disorders, were also discussed. R&D expenses were CHF 0.2 million, and G&A expenses were CHF 0.5 million for Q3 2025, both stable year-over-year. The call concluded with a Q&A session, during which the commercial outlook for chronic refractory cough, competitive landscape in post-stroke recovery, and potential developments with Indivior were addressed.Addex Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
70
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 29.97K | 404.10K | 1.61M | 1.42M | 2.92M |
| Gross Profit | 29.97K | 404.10K | 1.61M | 1.42M | 2.92M |
| EBITDA | -6.83M | -4.65M | -2.19M | -10.45M | -14.94M |
| Net Income | -6.73M | 7.06M | -10.56M | -20.80M | -15.35M |
Balance Sheet | |||||
| Total Assets | 6.37M | 10.68M | 4.64M | 8.28M | 22.54M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 3.35M | 3.87M | 6.96M | 20.50M |
| Total Debt | 34.73K | 41.99K | 344.34K | 373.13K | 482.01K |
| Total Liabilities | 1.60M | 1.00M | 3.50M | 3.37M | 5.61M |
| Stockholders Equity | 4.77M | 9.68M | 1.15M | 4.91M | 16.93M |
Cash Flow | |||||
| Free Cash Flow | -2.08M | -5.37M | -8.00M | -16.44M | -14.74M |
| Operating Cash Flow | -2.08M | -5.37M | -7.99M | -16.44M | -14.71M |
| Investing Cash Flow | -650.08K | 4.65M | -6.84K | 2.97K | -30.31K |
| Financing Cash Flow | 1.13M | 104.92K | 5.26M | 3.10M | 16.40M |
Addex Therapeutics Technical Analysis
Negative
8.23
Price Trends
6.71
Negative
6.87
Negative
7.73
Negative
Market Momentum
-0.16
Positive
45.42
Neutral
20.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXN, the sentiment is Negative. The current price of 8.23 is above the 20-day moving average (MA) of 6.50, above the 50-day MA of 6.71, and above the 200-day MA of 7.73, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 45.42 is Neutral, neither overbought nor oversold. The STOCH value of 20.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADXN.
Addex Therapeutics Risk Analysis
Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Addex Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $11.21M | -0.95 | -32.58% | ― | -100.00% | 13.00% | |
49 Neutral | $6.41M | -2.87 | -60.33% | ― | 23.52% | 48.34% | |
48 Neutral | $7.95M | -0.17 | -253.43% | ― | ― | 97.61% | |
44 Neutral | $6.72M | -0.94 | -71.27% | ― | -55.97% | -198.81% | |
44 Neutral | $7.81M | ― | -102.39% | ― | 356.16% | 62.82% |
* Healthcare Sector Average
ADXN
Addex Therapeutics
6.20
-2.01
-24.48%
KPRX
Kiora Pharmaceuticals
2.53
-0.60
-19.17%
XBIO
Xenetic Biosciences
2.80
0.06
2.19%
NCNA
Nucana
1.91
-15.87
-89.26%
CELZ
Creative Medical Technology Holdings
2.23
-0.21
-8.61%
HCWB
HCW Biologics
1.09
-3.58
-76.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.